In our previous paper, about the management of PV during COVID-19 pandemic, we emphasized that the impact of active pemphigus lesions, especially in oral or nasal mucosa, should also be taken into account and patient should not be left untreated because of the unreasonable fear of fatal outcomes ([1]). Dear Editor, Treatment of pemphigus vulgaris (PV) patients, as a chronic bullous disease, with immunosuppressive agents could affect the course of COVID-19 ([1]). We aimed to perform a tele-dermatology study to evaluate the outcome of PV patients who had received rituximab treatment within five years of COVID-19 pandemic. [Extracted from the article]